HOLON, Israel, April 3,
2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:
CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company
and a pioneer in computational target discovery,
today announced that management will participate in the
following upcoming investor conferences in April:
23rd Annual Needham Virtual Healthcare
Conference
Date: Wednesday,
April 10, 2024, at 8:00 AM
ET
Location: Virtual
Format: Presentation
Canaccord Genuity Horizons in Oncology Virtual
Conference
Date: Monday, April
15, 2024, at 9:00 AM ET
Location: Virtual
Format: Panel: Novel Immune Checkpoints - There's more than
one way to stimulate a T-cell
Live webcast of the presentation and a replay will be available
on the Investor Relations section of Compugen's website at
www.cgen.com. Live webcast of the panel and a replay will be
available by contacting your representative at Canaccord
Genuity.
About Compugen
Compugen is a clinical-stage
therapeutic discovery and development company utilizing its broadly
applicable predictive computational discovery capabilities to
identify new drug targets and biological pathways for developing
cancer immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT
component is derived from Compugen's clinical stage anti-TIGIT
antibody, COM902, in Phase 3 development by AstraZeneca through a
license agreement for the development of bispecific and
multispecific antibodies. In addition, Compugen's therapeutic
pipeline of early-stage immuno-oncology programs consists of
programs aiming to address various mechanisms of immune resistance,
of which the most advanced program, in IND enabling studies is
COM503, which is licensed to Gilead. COM503 is a potential
first-in-class, high affinity antibody which blocks the interaction
between IL-18 binding protein and IL-18, thereby freeing natural
IL-18 in the tumor microenvironment to inhibit cancer growth.
Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne
Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-two-upcoming-investor-conferences-302107006.html
SOURCE Compugen Ltd.